Cargando…
The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera
To assess the impact of the key non-synonymous amino acid substitutions in the RBD of the spike protein of SARS-CoV-2 variant B.1.617.1 (dominant variant identified in the current India outbreak) on the infectivity and neutralization activities of the immune sera, L452R and E484Q (L452R-E484Q varian...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385834/ https://www.ncbi.nlm.nih.gov/pubmed/35693215 http://dx.doi.org/10.1093/pcmedi/pbab016 |
_version_ | 1783742164910473216 |
---|---|
author | Li, Gen Zhou, Zhongcheng Du, Peng Yu, Meixing Li, Ning Xiong, Xinxin Huang, Hong Liu, Zhihai Dai, Qinjin Zhu, Jie Guo, Chengbin Wu, Shanyun Baptista-Hon, Daniel T Miao, Man Ming, Lam Wai Wu, Yong Zeng, Fanxin Zhang, Charlotte L Zhang, Edward D Song, Haifeng Liu, Jianghai Lau, Johnson Yiu-Nam Xiang, Andy P Zhang, Kang |
author_facet | Li, Gen Zhou, Zhongcheng Du, Peng Yu, Meixing Li, Ning Xiong, Xinxin Huang, Hong Liu, Zhihai Dai, Qinjin Zhu, Jie Guo, Chengbin Wu, Shanyun Baptista-Hon, Daniel T Miao, Man Ming, Lam Wai Wu, Yong Zeng, Fanxin Zhang, Charlotte L Zhang, Edward D Song, Haifeng Liu, Jianghai Lau, Johnson Yiu-Nam Xiang, Andy P Zhang, Kang |
author_sort | Li, Gen |
collection | PubMed |
description | To assess the impact of the key non-synonymous amino acid substitutions in the RBD of the spike protein of SARS-CoV-2 variant B.1.617.1 (dominant variant identified in the current India outbreak) on the infectivity and neutralization activities of the immune sera, L452R and E484Q (L452R-E484Q variant), pseudotyped virus was constructed (with the D614G background). The impact on binding with the neutralizing antibodies was also assessed with an ELISA assay. Pseudotyped virus carrying a L452R-E484Q variant showed a comparable infectivity compared with D614G. However, there was a significant reduction in the neutralization activity of the immune sera from non-human primates vaccinated with a recombinant receptor binding domain (RBD) protein, convalescent patients, and healthy vaccinees vaccinated with an mRNA vaccine. In addition, there was a reduction in binding of L452R-E484Q-D614G protein to the antibodies of the immune sera from vaccinated non-human primates. These results highlight the interplay between infectivity and other biologic factors involved in the natural evolution of SARS-CoV-2. Reduced neutralization activities against the L452R-E484Q variant will have an impact on health authority planning and implications for the vaccination strategy/new vaccine development. |
format | Online Article Text |
id | pubmed-8385834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-83858342021-09-01 The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera Li, Gen Zhou, Zhongcheng Du, Peng Yu, Meixing Li, Ning Xiong, Xinxin Huang, Hong Liu, Zhihai Dai, Qinjin Zhu, Jie Guo, Chengbin Wu, Shanyun Baptista-Hon, Daniel T Miao, Man Ming, Lam Wai Wu, Yong Zeng, Fanxin Zhang, Charlotte L Zhang, Edward D Song, Haifeng Liu, Jianghai Lau, Johnson Yiu-Nam Xiang, Andy P Zhang, Kang Precis Clin Med Research Article To assess the impact of the key non-synonymous amino acid substitutions in the RBD of the spike protein of SARS-CoV-2 variant B.1.617.1 (dominant variant identified in the current India outbreak) on the infectivity and neutralization activities of the immune sera, L452R and E484Q (L452R-E484Q variant), pseudotyped virus was constructed (with the D614G background). The impact on binding with the neutralizing antibodies was also assessed with an ELISA assay. Pseudotyped virus carrying a L452R-E484Q variant showed a comparable infectivity compared with D614G. However, there was a significant reduction in the neutralization activity of the immune sera from non-human primates vaccinated with a recombinant receptor binding domain (RBD) protein, convalescent patients, and healthy vaccinees vaccinated with an mRNA vaccine. In addition, there was a reduction in binding of L452R-E484Q-D614G protein to the antibodies of the immune sera from vaccinated non-human primates. These results highlight the interplay between infectivity and other biologic factors involved in the natural evolution of SARS-CoV-2. Reduced neutralization activities against the L452R-E484Q variant will have an impact on health authority planning and implications for the vaccination strategy/new vaccine development. Oxford University Press 2021-07-30 /pmc/articles/PMC8385834/ /pubmed/35693215 http://dx.doi.org/10.1093/pcmedi/pbab016 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the West China School of Medicine & West China Hospital of Sichuan University. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Li, Gen Zhou, Zhongcheng Du, Peng Yu, Meixing Li, Ning Xiong, Xinxin Huang, Hong Liu, Zhihai Dai, Qinjin Zhu, Jie Guo, Chengbin Wu, Shanyun Baptista-Hon, Daniel T Miao, Man Ming, Lam Wai Wu, Yong Zeng, Fanxin Zhang, Charlotte L Zhang, Edward D Song, Haifeng Liu, Jianghai Lau, Johnson Yiu-Nam Xiang, Andy P Zhang, Kang The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera |
title | The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera |
title_full | The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera |
title_fullStr | The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera |
title_full_unstemmed | The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera |
title_short | The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera |
title_sort | sars-cov-2 spike l452r-e484q variant in the indian b.1.617 strain showed significant reduction in the neutralization activity of immune sera |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385834/ https://www.ncbi.nlm.nih.gov/pubmed/35693215 http://dx.doi.org/10.1093/pcmedi/pbab016 |
work_keys_str_mv | AT ligen thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zhouzhongcheng thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT dupeng thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT yumeixing thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT lining thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT xiongxinxin thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT huanghong thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT liuzhihai thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT daiqinjin thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zhujie thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT guochengbin thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT wushanyun thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT baptistahondanielt thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT miaoman thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT minglamwai thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT wuyong thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zengfanxin thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zhangcharlottel thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zhangedwardd thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT songhaifeng thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT liujianghai thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT laujohnsonyiunam thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT xiangandyp thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zhangkang thesarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT ligen sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zhouzhongcheng sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT dupeng sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT yumeixing sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT lining sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT xiongxinxin sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT huanghong sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT liuzhihai sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT daiqinjin sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zhujie sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT guochengbin sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT wushanyun sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT baptistahondanielt sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT miaoman sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT minglamwai sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT wuyong sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zengfanxin sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zhangcharlottel sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zhangedwardd sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT songhaifeng sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT liujianghai sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT laujohnsonyiunam sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT xiangandyp sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera AT zhangkang sarscov2spikel452re484qvariantintheindianb1617strainshowedsignificantreductionintheneutralizationactivityofimmunesera |